Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
546.85B
Market cap546.85B
Price-Earnings ratio
26.27
Price-Earnings ratio26.27
Dividend yield
2.29%
Dividend yield2.29%
Average volume
7.88M
Average volume7.88M
High today
High today
Low today
Low today
Open price
$229.00
Open price$229.00
Volume
6.65K
Volume6.65K
52 Week high
$251.71
52 Week high$251.71
52 Week low
$146.12
52 Week low$146.12

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $226.25, with a market capitalization of 546.85B. The stock trades at a price-to-earnings (P/E) ratio of 26.27 and offers a dividend yield of 2.3%.

On 2026-05-04, Johnson & Johnson(JNJ) shares started trading at $229.00, with intraday highs of — and lows of —.

Trading volume for Johnson & Johnson(JNJ) stock has reached 6.65K, versus its average volume of 7.88M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $146.12.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $146.12.

JNJ News

Simply Wall St 2d
Pipeline Wins And Dividend Hike Might Change The Case For Investing In Johnson & Johnson

In late April 2026, Johnson & Johnson reported strong first‑quarter results with revenue of US$24.06 billion, raised its full‑year sales outlook to US$100.30–US...

Pipeline Wins And Dividend Hike Might Change The Case For Investing In Johnson & Johnson
Benzinga 3d
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner

As the S&P 500 seeks the next leg higher, smart money might be moving toward healthcare, a sleeper sector of 2026. Still, the series of earnings upgrades, coupl...

S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
Simply Wall St 3d
UK Talc Case Puts Spotlight On Johnson & Johnson Valuation And Risks

The UK High Court has begun hearing what is expected to be the largest product liability case in UK history against Johnson & Johnson (NYSE:JNJ). Thousands of...

UK Talc Case Puts Spotlight On Johnson & Johnson Valuation And Risks

Analyst ratings

61%

of 28 ratings
Buy
60.7%
Hold
32.1%
Sell
7.1%

More JNJ News

TipRanks 4d
Johnson & Johnson appoints Koors as Vice President, Investor Relations

Johnson & Johnson announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Koors will report to Johnson & Johnson’s...

The Motley Fool 4d
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering

When you think of the path to wealth, you might immediately think of supercharged technology stocks -- players that may have delivered double or even triple-dig...

Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering
Simply Wall St 4d
Johnson And Johnson Trial Puts Boston Scientific Growth Story Under Scrutiny

Johnson & Johnson has launched a head to head clinical trial comparing its Varipulse Pro pulsed field ablation system with Boston Scientific's FARAPULSE platfor...

Johnson And Johnson Trial Puts Boston Scientific Growth Story Under Scrutiny
TipRanks 5d
Underappreciated Autoimmune Franchise Potential Keeps Johnson & Johnson at Buy with Unchanged $275 Price Target

Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Johnson & Johnson and keeping the price target at $275.00. Claim 55% Off TipRanks Unlock hedge...

Simply Wall St 6d
Is It Time To Reassess Johnson & Johnson After Its Strong 1 Year Share Price Run?

If you are asking whether Johnson & Johnson at around US$227.79 is still a reasonable entry or more of a hold for now, you will want to look closely at what the...

Is It Time To Reassess Johnson & Johnson After Its Strong 1 Year Share Price Run?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.